EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

High expression of insulinoma‐associated protein 1 ( INSM1 ) distinguishes colorectal mixed and pure neuroendocrine carcinomas from conventional adenocarcinomas with diffuse expression of synaptophysin

Anne-Sophie Litmeyer, Björn Konukiewitz, Atsuko Kasajima, Sebastian Foersch, Felix Schicktanz, Maxime Schmitt, Franziska Kellers, Albert Grass, Paul Jank iD, Bettina Lehman, Thomas M Gress, Anja Rinke und 5 weitere

The Journal of Pathology: Clinical Research · 2023

DOI: 10.1002/cjp2.339 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2023. Verfasst von Anne-Sophie Litmeyer und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, Phillips University Marburg and University Hospital Marburg, Marburg, Germany. Hauptthemen laut MEDLINE: Synaptophysin, Biomarkers, Tumor, Carcinoma, Neuroendocrine, Colorectal Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Complementary to synaptophysin and chromogranin A, insulinoma‐associated protein 1 (INSM1) has emerged as a sensitive marker for the diagnosis of neuroendocrine neoplasms. Since there are no comparative data regarding INSM1 expression in conventional colorectal adenocarcinomas (CRCs) and colorectal mixed adenoneuroendocrine carcinomas/neuroendocrine carcinomas (MANECs/NECs), we examined INSM1 in a large cohort of conventional CRCs and MANECs/NECs. In conventional CRC, we put a special focus on conventional CRC with diffuse expression of synaptophysin, which carry the risk of being misinterpreted as a MANEC or a NEC. We investigated INSM1 according to the immunoreactive score in our main cohort of 1,033 conventional CRCs and 21 MANECs/NECs in comparison to the expression of synaptophysin and chromogranin A and correlated the results with clinicopathological parameters and patient survival. All MANECs/NECs expressed INSM1, usually showing high or moderate expression (57% high, 34% moderate, and 9% low), which distinguished them from conventional CRCs, which were usually INSM1 negative or low, even if they diffusely expressed synaptophysin. High expression of INSM1 was not observed in conventional CRCs. Chromogranin A was negative/low in most conventional CRCs (99%), but also in most MANECs/NECs (66%). Comparable results were observed in our independent validation cohorts of conventional CRC ( n = 274) and MANEC/NEC ( n = 19). Similar to synaptophysin, INSM1 expression had no prognostic relevance in conventional CRCs, while true MANEC/NEC showed a highly impaired survival in univariate and multivariate analyses (e.g. disease‐specific survival: p < 0.001). MANECs/NECs are a highly aggressive variant of colorectal cancer, which must be reliably identified. High expression of INSM1 distinguishes MANEC/NEC from conventional CRCs with diffuse expression of the standard neuroendocrine marker synaptophysin, which do not share the same dismal prognosis. Therefore, high INSM1 expression is a highly specific/sensitive marker that is supportive for the diagnosis of true colorectal MANEC/NEC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SynaptophysinBiomarkers, TumorCarcinoma, NeuroendocrineColorectal NeoplasmsRepressor ProteinsAdenocarcinomaHumansMaleFemaleMiddle AgedAgedChromogranin AAdultAged, 80 and overDiagnosis, DifferentialImmunohistochemistryPrognosis

Stichwörter der Autor:innen

INSM1colorectal carcinomaconventional adenocarcinomaneuroendocrine carcinomasynaptophysin

Substanzen

INSM1 protein, humanSynaptophysinBiomarkers, TumorRepressor ProteinsChromogranin ASYP protein, human

Autor:innen und Institutionen

  • Institute of Pathology, Phillips University Marburg and University Hospital Marburg, Marburg, Germany.
  • Department of Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Christian-Albrechts-Universität zu Kiel, Kiel, Germany.
  • Institute of Pathology, Technical University of Munich, Munich, Germany.
  • Institute of Pathology, University Hospital Mainz, Mainz, Germany.
  • Department of Surgery, Phillips University Marburg and University Hospital Marburg, Marburg, Germany.
  • Department of Gastroenterology, Endocrinology and Infectious Diseases, Phillips University Marburg and University Hospital Marburg, Marburg, Germany.

ORCID-Profile: Paul Jank, Moritz Jesinghaus

Zitieren

APA

Litmeyer, A. S., Konukiewitz, B., Kasajima, A., Foersch, S., Schicktanz, F., Schmitt, M., Kellers, F., Grass, A., Jank, P., Lehman, B., Gress, T. M., Rinke, A., Bartsch, D. K., Denkert, C., Weichert, W., Klöppel, G., & Jesinghaus, M. (2023). High expression of insulinoma‐associated protein 1 ( INSM1 ) distinguishes colorectal mixed and pure neuroendocrine carcinomas from conventional adenocarcinomas with diffuse expression of synaptophysin. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/cjp2.339

Vancouver

Litmeyer AS, Konukiewitz B, Kasajima A, Foersch S, Schicktanz F, Schmitt M, et al. High expression of insulinoma‐associated protein 1 ( INSM1 ) distinguishes colorectal mixed and pure neuroendocrine carcinomas from conventional adenocarcinomas with diffuse expression of synaptophysin. The Journal of Pathology: Clinical Research. 2023. doi:10.1002/cjp2.339

BibTeX
@article{Litmeyer2023,
  author = {Litmeyer, Anne-Sophie and Konukiewitz, Björn and Kasajima, Atsuko and Foersch, Sebastian and Schicktanz, Felix and Schmitt, Maxime and Kellers, Franziska and Grass, Albert and Jank, Paul and Lehman, Bettina and Gress, Thomas M and Rinke, Anja and Bartsch, Detlef K and Denkert, Carsten and Weichert, Wilko and Klöppel, Günter and Jesinghaus, Moritz},
  title = {High expression of insulinoma‐associated protein 1 ( INSM1 ) distinguishes colorectal mixed and pure neuroendocrine carcinomas from conventional adenocarcinomas with diffuse expression of synaptophysin},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2023},
  doi = {10.1002/cjp2.339}
}
Kostenlos starten →